HSc(Mcd) (I Ions I) MBBS PhD FRAC P FRC PC FR.CPA, A LLAN W RIPPS BSc (I Inn, I) PhD, D IANA CT A YLOR B Arri ,'c PhD, LO IS A Mc SJ IANE BSc( Dir Ed), V ICTOR J W EBSTER MBBS FRCS FRACS RL CLANCY, AW CRIPPS, DC TAYLOR, LA MCSHANE, VJ WEBSTER. Detection of antibody against HeLicobacter pylori in the saliva of patients with dyspepsia. Can J Gastroenterol 1994;8( 7):408-412. There is a need to develop no ninva -ivc assays to detect Helicobaccer pylori infec tion in the gas tric mucosa, C urrent dogma predi cs char the presence of antibody within sa li va should accurately reflect contemporary coloni za ti on of the gut muco a. This study examined the clinical value of a saliva enzyme-linked immunoadsorbent assay (ELISA) fo r anti -H pylori antibody, compared with the serum EU A assay, and found the sen iti vity of the ali va assay was 89%, specificity 94%, accuracy 93%, po itive predicti ve value 89% and negative predi tive va lue 94%. Assessment foll owing eradi cati on therapy demonstra ted that sali vary antibody wa a more sensiti ve indicato r of coloniza tion than wa crum antibody. The immunoglobulin G antibody in sali va corrclarcd best with colo ni zation , and regression analyti is was most consistent with a loca l production of antibody. These results indi cate that lerecrio n of antibody in sali va contribu tes to diagnosis and management of H pylori infectio n.
H EU C013ACTER PYLO RI IS A MAJOR
cause of gastriti s ( 1,2 ) a nd erad icatio n of in fec tio n is now recomme nded , at least in patie n ts wit h assoc iated pe pt ic ulcer di sease (3) . Inc reas ingly, at te ntio n has bee n paid to t he di ag nos is of infect io n using no nin vasive test to e nab le both se lect ive endoscopy (4 ,5) a nd t he in itiatio n of logica l manageme n t-S uch tests sho uld ass ist the furth er e pide mio log ica l assessme n t of the effec ts of age, race and e nv ironme n tal fac tors on infect io n with H /Jylori inc lud ing the link be tween c h ro nic in fect ion and gast ri c ca nce r ( 6, 7) .
The detectio n of scrum a ntibod y is a sensitive a nd spec ific assay fo r infection with ad van rngcs over urea breath tests, t he c urre ntl y ava il able a lte rnative to sero logica l di agnos is (8, 9 ) . Indeed, it has been recomme nded t hat sc rum a nt ibody assay sho uld replace c ndo ·copy as t he ini tial investigat io n of d yspeps ia in subjects yo unger th an 4 5 yea rs (4 ), Sc rum a nti bod y lcve b , however, respond slow ly to a cha nge in H pylori sta tus (1 0) and have ce rta in technical diffic ul t ies in pat ien t manage me n t, leav ing roo m fo r a n a lte rnative non invas ive assay to de tect infect io n . W e, th e refore, compa red the prese nce and level of sa li vary a n tibod y to H /)ylori with a serum test in subjects wi th dyspepsia to dete rmine the va lue of a sali va a nti bod y assay in mon itoring infec ti on, were referred for endoscopy. infection with H pylori was established via biopsy of the gastric antrum by demonstration of bacteria by histology or by detection of urea e production. Subjects with a positive urease test were offered eradication therapy consisting of colloida l bismuth subcirrate (2xl08 mg), metronidazole (400 mg) and amoxycillin trihydrate (500 mg). Bismuth was administered every 12 h for four weeks while metronidazole and amoxyci llin trihydrate were administered every 8 h for two weeks. The treated group was re-endoscoped eight weeks after beginning antimicrobial therapy and reasessed for the presence of H /)ylori. In addition, unstimulated saliva and ·crum were collected at study start and at the post-treatment visit. lmmunoglobulin G (IgG) antibody to H pylori was measured using an enzyme-linked immunoadsorbent assay (ELISA). Separate assay systems have been developed for serum and saliva (11 ). These assays u e a purified high molecular weight antigen, and the saliva assay has been commercially developed by Cortecs Diagnostics (Deeside, United Kingdom). Comparison of saliva ELISA for anti-H pylori antibody with the serum ELISA assay: The database obtained from the 134 patients was used to determine the clinical value characteristics of salivary antibody detection against the sero logical results. Sensitivity of the saliva assay was 89%, specificity 94%, accuracy 93%, po itive predictive value 89% and negative predictive value 94%. Regression analysis of lgG anti-H pylori antibody from paired serum and saliva samples ( Figure 2 ) (r2=0.55) was most consistent with a contribution to antibody in saliva from local synthesis. Effect of eradication treatment on saliva anti-H pylori antibody four weeks post-treatment: Twenty-four patients with evidence ofH pylori infection were given eradication therapy and reassessed four weeks after completion of treatment. Eradication therapy was given to patients whose gastric biopsies te red positive for urease activity, except in the case of one patient with positive histology for H pylori and a negative urease test. Half of the patients with a positive saliva test became sa liva-negative (Table 1) , more than twice the percentage that became seronegative. If a reduction in antibody titre of more than 50% was assessed ( Table 2) , less than half the serum test resu lts were reduced by at least 50% while the result for saliva (83%) was of the ame order The pretreatment level of salivary antibody was a major determinant of the time taken to fall in response to antim icrobial treatment (Tables 3,4 ) . Thus for four-week post-treatment negative sa liva tests, the mean pretreatment antibody level was 1.5 ELISA units (EU)/mL compared with 3.3 EU/ml for those who remained positive but at le s than 50% of pretreatment values. For those not fa lling below the 50% level, the pretreatment level was 5.0 EU/ml. Three patients in this la t group tested at six months showed leve ls less than 50% (n=2) or negative (n= 1) for saliva antibody .
PATIENTS AND METHODS

RESULTS
Eradication was not achieved by four weeks in three patients ( Table 1,  patient 10; Table 3 , patients 5 and 6). Salivary antibody fe ll in all three at four weeks. This fa ll in antibody level probably reflects a response to partial eradication of bacteria as judged by im provement in both clinical and laboratory (seroconversion and reversal of a po itive urease test) parameters. disappearance of serum antibody was about half that of salivary antibody. The rate of fall in serum antibody concentration, however, was faster than rates previously reported using tests that contained crude bacterial extract for antigen (10) . Patient with high saliva (and serum) antibody levels took longer to revert to negative following successful eradication therapy. With standard criteria, three patients failed to eradicate H pylori, all of whom had a fall in salivary antibody. Two of these patients had histological, serological and clinical evidence of a partial response to antimicrobial therapy. Two of the three had high pre-therapy levels of antibody, suggesting that high levels of antibody may predict a risk group for failure LO eraJicate bacteria. An early 'dip' in serum antiboJy following eradication therapy has also been noteJ in patients with a partial response to therapy ( lO). A lo nge r period of observation is needed to define the kinetics of rhe salivary ant ibody response to erad ication treatm nt ancl to determine any clinical va lue in identifying subject at risk of fa iling eradication therapy. An important group of patients with dyspepsia was urease-and histology negative (5.2% of total stud y group) but had H pylori antibody in both serum and saliva. ix of the seven patients in this group had chronic gastritis, two of whom also had changes in acute inflammation . lt is likely thar gastritis in the e patients is associated will, a low level of infection not detected by clasical rests. This concept is consistent with the obse rvation of reversal of damage with antimicrobial therapy in the ahsence of detectable infection ( 12) , and of the ,ign ifi cant numbers of patients with peptic ulcer without identifiable cause (13, 14) . Eradication therapy monitored with salivary anribody levels and polymerase chain reaction ana lysis of biopsy material (15) may estab lish infection as a basis of gastritis in a proportion of these patients.
DISCUSSION
The source of the [gG antibody in aliva is not clear but is consistent with previous demonstrations of lgG antibody following mucosa! stimu lation with microbial antigens ( 16, l 7) . ln animal models, secretory [gG antihody correlates with the kin tics of local lgA secretion anJ does not clo ely fo llow serum levels (18) , suggesting that local synthesi · from gut-derived lymphocytes may contribute to the lgG antibody pool in ·ecretiom. Further support for local secretion of [gG was gained from the observation of lgG-containing plasma cell within the respiratory muco a following intestinal immunization (19) . This concept is consistent with
